Cargando…

A VSV-based assay quantifies coronavirus Mpro/3CLpro/Nsp5 main protease activity and chemical inhibition

Protease inhibitors are among the most powerful antiviral drugs. However, for SARS-CoV-2 only a small number of protease inhibitors have been identified thus far and there is still a great need for assays that efficiently report protease activity and inhibition in living cells. Here, we engineer a s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heilmann, Emmanuel, Costacurta, Francesco, Geley, Stephan, Mogadashi, Seyad Arad, Volland, Andre, Rupp, Bernhard, Harris, Reuben Stewart, von Laer, Dorothee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9046202/ https://www.ncbi.nlm.nih.gov/pubmed/35478219 http://dx.doi.org/10.1038/s42003-022-03277-0

Ejemplares similares

SARS-CoV-2 3CL(pro) mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376
por: Heilmann, Emmanuel, et al.
Publicado: (2022)

A comprehensive study of SARS-CoV-2 main protease (M(pro)) inhibitor-resistant mutants selected in a VSV-based system
por: Costacurta, Francesco, et al.
Publicado: (2023)

Structural and Biochemical Analysis of the Dual Inhibition of MG-132 against SARS-CoV-2 Main Protease (Mpro/3CLpro) and Human Cathepsin-L
por: Costanzi, Elisa, et al.
Publicado: (2021)

Discovery of 3CLpro inhibitor of SARS-CoV-2 main protease
por: Kuang, Yi, et al.
Publicado: (2023)

Natural Products-Based Drug Design against SARS-CoV-2 Mpro 3CLpro
por: Silva, Rai C., et al.
Publicado: (2021)

Studies on antiviral resistant SARS-CoV-2 Mpro mutants
por: Esler, Morgan A., et al.
Publicado: (2023)

Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors
por: Moghadasi, Seyed Arad, et al.
Publicado: (2022)

Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors
por: Moghadasi, Seyed Arad, et al.
Publicado: (2023)

Recognition of Natural Products as Potential Inhibitors of COVID-19 Main Protease (Mpro): In-Silico Evidences
por: Narkhede, Rohan R., et al.
Publicado: (2020)

Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors
por: Amin, Sk. Abdul, et al.
Publicado: (2021)

Potential Resistance of SARS-CoV-2 Main Protease (Mpro) against Protease Inhibitors: Lessons Learned from HIV-1 Protease
por: Mótyán, János András, et al.
Publicado: (2022)

Evolutionary aspects of mutation in functional motif and post-translational modifications in SARS-CoV-2 3CLpro (Mpro): an in-silico study
por: Gupta, Amit, et al.
Publicado: (2023)

Dual inhibition of COVID-19 spike glycoprotein and main protease 3CLpro by Withanone from Withania somnifera
por: Patil, Vishal Shivalingappa, et al.
Publicado: (2021)

A Study of Drug Repurposing to Identify SARS-CoV-2 Main Protease (3CLpro) Inhibitors
por: Jo, Seri, et al.
Publicado: (2022)

The main protease 3CLpro of the SARS-CoV-2 virus: how to turn an enemy into a helper
por: Belenkaya, Svetlana V., et al.
Publicado: (2023)

The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma
por: Kimpel, Janine, et al.
Publicado: (2018)

Computational Simulation of HIV Protease Inhibitors to the Main Protease (Mpro) of SARS-CoV-2: Implications for COVID-19 Drugs Design
por: Yu, Wei, et al.
Publicado: (2021)

Biochemical and biophysical characterization of the main protease, 3-chymotrypsin-like protease (3CLpro) from the novel coronavirus SARS-CoV 2
por: Ferreira, Juliana C., et al.
Publicado: (2020)

Dimethyl sulfoxide reduces the stability but enhances catalytic activity of the main SARS‐CoV‐2 protease 3CLpro
por: Ferreira, Juliana C., et al.
Publicado: (2021)

Key dimer interface residues impact the catalytic activity of 3CLpro, the main protease of SARS-CoV-2
por: Ferreira, Juliana C., et al.
Publicado: (2022)

Corrigendum: The main protease 3CLpro of the SARS-CoV-2 virus: how to turn an enemy into a helper
por: Belenkaya, Svetlana V., et al.
Publicado: (2023)

Coagulation modifiers targeting SARS-CoV-2 main protease Mpro for COVID-19 treatment: an in silico approach
por: Biembengut, Ísis Venturi, et al.
Publicado: (2020)

Oncolytic activity of the rhabdovirus VSV‐GP against prostate cancer
por: Urbiola, Carles, et al.
Publicado: (2018)

Structure-based screening of novel lichen compounds against SARS Coronavirus main protease (Mpro) as potentials inhibitors of COVID-19
por: Joshi, Tanuja, et al.
Publicado: (2020)

Discovery of novel inhibitors against main protease (Mpro) of SARS-CoV-2 via virtual screening and biochemical evaluation
por: Guo, Sheng, et al.
Publicado: (2021)

Investigation of structural analogs of hydroxychloroquine for SARS-CoV-2 main protease (Mpro): A computational drug discovery study
por: Reyaz, Saima, et al.
Publicado: (2021)

Finding potential inhibitors for Main protease (Mpro) of SARS-CoV-2 through virtual screening and MD simulation studies
por: Ahamed, N. Anis, et al.
Publicado: (2023)

E3 ubiquitin ligase ZBTB25 suppresses beta coronavirus infection through ubiquitination of the main viral protease MPro
por: Lear, Travis B., et al.
Publicado: (2023)

Cell-Based High-Throughput Screening Protocol for Discovering Antiviral Inhibitors Against SARS-COV-2 Main Protease (3CLpro)
por: Rothan, Hussin A., et al.
Publicado: (2021)

Heparan sulfate proteoglycans serve as alternative receptors for low affinity LCMV variants
por: Volland, André, et al.
Publicado: (2021)

Molecular modeling and simulations of some antiviral drugs, benzylisoquinoline alkaloid, and coumarin molecules to investigate the effects on Mpro main viral protease inhibition
por: Mir, Showkat Ahmad, et al.
Publicado: (2023)

Rutin Is a Low Micromolar Inhibitor of SARS-CoV-2 Main Protease 3CLpro: Implications for Drug Design of Quercetin Analogs
por: Rizzuti, Bruno, et al.
Publicado: (2021)

Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach
por: Gupta, Yash, et al.
Publicado: (2021)

Multistep rational molecular design and combined docking for discovery of novel classes of inhibitors of SARS-CoV-2 main protease 3CLpro
por: Tumskiy, Roman S., et al.
Publicado: (2021)

Biflavonoid as potential 3-chymotrypsin-like protease (3CLpro) inhibitor of SARS-Coronavirus
por: Hartini, Yustina, et al.
Publicado: (2021)

Dietary polyphenols mitigate SARS-CoV-2 main protease (Mpro)–Molecular dynamics, molecular mechanics, and density functional theory investigations
por: Adelusi, Temitope Isaac, et al.
Publicado: (2022)

Identification of SARS-CoV-2 Main Protease (Mpro) Cleavage Sites Using Two-Dimensional Electrophoresis and In Silico Cleavage Site Prediction
por: Miltner, Noémi, et al.
Publicado: (2023)

Synthesis, Molecular Docking, and Dynamic Simulation Targeting Main Protease (Mpro) of New, Thiazole Clubbed Pyridine Scaffolds as Potential COVID-19 Inhibitors
por: Alghamdi, Adel, et al.
Publicado: (2023)

The Methyltransferase Region of Vesicular Stomatitis Virus L Polymerase Is a Target Site for Functional Intramolecular Insertion
por: Heilmann, Emmanuel, et al.
Publicado: (2019)

Evaluation of Xa inhibitors as potential inhibitors of the SARS-CoV-2 Mpro protease
por: Papaj, Katarzyna, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rdaape1v0ocp3h0nersprm4at9